Eli Lilly and Co.

Lilly Corporate Center,
Indianapolis, Indiana 46285
United States,
(317) 276-2000

Eli Lilly and Company discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Eli Lilly was originally established in 1876 and is headquartered in Indianapolis, Indiana.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.0/yr) # 16 1 1 - 1 2 21
vol $14.2B $5.4B $960M $1.7B $22.3B
Sell (0.2/yr) # 7 1 - - - - 8
vol $1.6B $410M $2.0B

Top M&A Advisors

Financial Deals
Sign-up to View
Sign-up to View
Sign-up to View
Legal Deals
Sign-up to View
Sign-up to View
Sign-up to View

Deal Values

> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest ImClone Systems, Inc.
$6.5B (2008-10-06)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest PCS Health Systems Inc.
$1.5B (1998-11-18)

According to our data here at Mergr, Eli Lilly has acquired 21 companies, including 5 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 8 assets.

Eli Lilly’s largest acquisition to date was in 2008, when it acquired ImClone Systems for $6.5B. It’s largest disclosed sale occurred in 1998, when it sold PCS Health Systems to Rite Aid for $1.5B. Eli Lilly has acquired in 8 different US states, and 4 countries. The Company’s most targeted sectors include life science (67%) and healthcare services (15%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 15 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 29 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 5 platform acquisitions.

Join Mergr and gain access to Eli Lilly’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.4K Private Equity Firms
  • 119K M&A Transactions
  • 129K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.